The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Therapy in Oncology Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Gene Therapy in Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Gene Therapy in Oncology market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Gene Therapy in Oncology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Ex Vivo segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Gene Therapy in Oncology include Bristol-Myers Squibb, Cold Genesys, Advantagene, Amgen, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Gene Therapy in Oncology market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ex Vivo
In Vivo
Market segment by Application, can be divided into
Hospitals
Diagnostics Centers
Research Institutes
Market segment by players, this report covers
Bristol-Myers Squibb
Cold Genesys
Advantagene
Amgen
AstraZeneca
Bio-Path Holdings
CRISPR Therapeutics
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck
Mologen AG
Oncolytics Biotech
Oncosec
Oncotelic
Shenzhen SiBiono GeneTech
Sillajen Biotherapeutics
Tocagen
UniQure
Ziopharm Oncology
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Gene Therapy in Oncology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Gene Therapy in Oncology, with revenue, gross margin and global market share of Gene Therapy in Oncology from 2019 to 2022.
Chapter 3, the Gene Therapy in Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Gene Therapy in Oncology market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Gene Therapy in Oncology research findings and conclusion, appendix and data source.
Geographical Area
Global
The Gene Therapy in Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Gene Therapy in Oncology market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Gene Therapy in Oncology global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Ex Vivo segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Gene Therapy in Oncology include Bristol-Myers Squibb, Cold Genesys, Advantagene, Amgen, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Gene Therapy in Oncology market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ex Vivo
In Vivo
Market segment by Application, can be divided into
Hospitals
Diagnostics Centers
Research Institutes
Market segment by players, this report covers
Bristol-Myers Squibb
Cold Genesys
Advantagene
Amgen
AstraZeneca
Bio-Path Holdings
CRISPR Therapeutics
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck
Mologen AG
Oncolytics Biotech
Oncosec
Oncotelic
Shenzhen SiBiono GeneTech
Sillajen Biotherapeutics
Tocagen
UniQure
Ziopharm Oncology
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Gene Therapy in Oncology product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Gene Therapy in Oncology, with revenue, gross margin and global market share of Gene Therapy in Oncology from 2019 to 2022.
Chapter 3, the Gene Therapy in Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Gene Therapy in Oncology market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Gene Therapy in Oncology research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Gene Therapy in Oncology
1.2 Classification of Gene Therapy in Oncology by Type
1.2.1 Overview: Global Gene Therapy in Oncology Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Gene Therapy in Oncology Revenue Market Share by Type in 2021
1.2.3 Ex Vivo
1.2.4 In Vivo
1.3 Global Gene Therapy in Oncology Market by Application
1.3.1 Overview: Global Gene Therapy in Oncology Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Diagnostics Centers
1.3.4 Research Institutes
1.4 Global Gene Therapy in Oncology Market Size & Forecast
1.5 Global Gene Therapy in Oncology Market Size and Forecast by Region
1.5.1 Global Gene Therapy in Oncology Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Gene Therapy in Oncology Market Size by Region, (2017-2022)
1.5.3 North America Gene Therapy in Oncology Market Size and Prospect (2017-2028)
1.5.4 Europe Gene Therapy in Oncology Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Gene Therapy in Oncology Market Size and Prospect (2017-2028)
1.5.6 South America Gene Therapy in Oncology Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Gene Therapy in Oncology Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Gene Therapy in Oncology Market Drivers
1.6.2 Gene Therapy in Oncology Market Restraints
1.6.3 Gene Therapy in Oncology Trends Analysis
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Product and Solutions
2.1.4 Bristol-Myers Squibb Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 Cold Genesys
2.2.1 Cold Genesys Details
2.2.2 Cold Genesys Major Business
2.2.3 Cold Genesys Gene Therapy in Oncology Product and Solutions
2.2.4 Cold Genesys Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Cold Genesys Recent Developments and Future Plans
2.3 Advantagene
2.3.1 Advantagene Details
2.3.2 Advantagene Major Business
2.3.3 Advantagene Gene Therapy in Oncology Product and Solutions
2.3.4 Advantagene Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Advantagene Recent Developments and Future Plans
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Gene Therapy in Oncology Product and Solutions
2.4.4 Amgen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Amgen Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Gene Therapy in Oncology Product and Solutions
2.5.4 AstraZeneca Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Bio-Path Holdings
2.6.1 Bio-Path Holdings Details
2.6.2 Bio-Path Holdings Major Business
2.6.3 Bio-Path Holdings Gene Therapy in Oncology Product and Solutions
2.6.4 Bio-Path Holdings Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Bio-Path Holdings Recent Developments and Future Plans
2.7 CRISPR Therapeutics
2.7.1 CRISPR Therapeutics Details
2.7.2 CRISPR Therapeutics Major Business
2.7.3 CRISPR Therapeutics Gene Therapy in Oncology Product and Solutions
2.7.4 CRISPR Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 CRISPR Therapeutics Recent Developments and Future Plans
2.8 Editas Medicine
2.8.1 Editas Medicine Details
2.8.2 Editas Medicine Major Business
2.8.3 Editas Medicine Gene Therapy in Oncology Product and Solutions
2.8.4 Editas Medicine Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Editas Medicine Recent Developments and Future Plans
2.9 Geron Corp
2.9.1 Geron Corp Details
2.9.2 Geron Corp Major Business
2.9.3 Geron Corp Gene Therapy in Oncology Product and Solutions
2.9.4 Geron Corp Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Geron Corp Recent Developments and Future Plans
2.10 Idera Pharmaceuticals
2.10.1 Idera Pharmaceuticals Details
2.10.2 Idera Pharmaceuticals Major Business
2.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Product and Solutions
2.10.4 Idera Pharmaceuticals Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Idera Pharmaceuticals Recent Developments and Future Plans
2.11 Intellia Therapeutics
2.11.1 Intellia Therapeutics Details
2.11.2 Intellia Therapeutics Major Business
2.11.3 Intellia Therapeutics Gene Therapy in Oncology Product and Solutions
2.11.4 Intellia Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Intellia Therapeutics Recent Developments and Future Plans
2.12 Johnson & Johnson
2.12.1 Johnson & Johnson Details
2.12.2 Johnson & Johnson Major Business
2.12.3 Johnson & Johnson Gene Therapy in Oncology Product and Solutions
2.12.4 Johnson & Johnson Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Johnson & Johnson Recent Developments and Future Plans
2.13 Marsala Biotech
2.13.1 Marsala Biotech Details
2.13.2 Marsala Biotech Major Business
2.13.3 Marsala Biotech Gene Therapy in Oncology Product and Solutions
2.13.4 Marsala Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Marsala Biotech Recent Developments and Future Plans
2.14 Merck
2.14.1 Merck Details
2.14.2 Merck Major Business
2.14.3 Merck Gene Therapy in Oncology Product and Solutions
2.14.4 Merck Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Merck Recent Developments and Future Plans
2.15 Mologen AG
2.15.1 Mologen AG Details
2.15.2 Mologen AG Major Business
2.15.3 Mologen AG Gene Therapy in Oncology Product and Solutions
2.15.4 Mologen AG Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Mologen AG Recent Developments and Future Plans
2.16 Oncolytics Biotech
2.16.1 Oncolytics Biotech Details
2.16.2 Oncolytics Biotech Major Business
2.16.3 Oncolytics Biotech Gene Therapy in Oncology Product and Solutions
2.16.4 Oncolytics Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Oncolytics Biotech Recent Developments and Future Plans
2.17 Oncosec
2.17.1 Oncosec Details
2.17.2 Oncosec Major Business
2.17.3 Oncosec Gene Therapy in Oncology Product and Solutions
2.17.4 Oncosec Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Oncosec Recent Developments and Future Plans
2.18 Oncotelic
2.18.1 Oncotelic Details
2.18.2 Oncotelic Major Business
2.18.3 Oncotelic Gene Therapy in Oncology Product and Solutions
2.18.4 Oncotelic Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Oncotelic Recent Developments and Future Plans
2.19 Shenzhen SiBiono GeneTech
2.19.1 Shenzhen SiBiono GeneTech Details
2.19.2 Shenzhen SiBiono GeneTech Major Business
2.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Product and Solutions
2.19.4 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Shenzhen SiBiono GeneTech Recent Developments and Future Plans
2.20 Sillajen Biotherapeutics
2.20.1 Sillajen Biotherapeutics Details
2.20.2 Sillajen Biotherapeutics Major Business
2.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Product and Solutions
2.20.4 Sillajen Biotherapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Sillajen Biotherapeutics Recent Developments and Future Plans
2.21 Tocagen
2.21.1 Tocagen Details
2.21.2 Tocagen Major Business
2.21.3 Tocagen Gene Therapy in Oncology Product and Solutions
2.21.4 Tocagen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Tocagen Recent Developments and Future Plans
2.22 UniQure
2.22.1 UniQure Details
2.22.2 UniQure Major Business
2.22.3 UniQure Gene Therapy in Oncology Product and Solutions
2.22.4 UniQure Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 UniQure Recent Developments and Future Plans
2.23 Ziopharm Oncology
2.23.1 Ziopharm Oncology Details
2.23.2 Ziopharm Oncology Major Business
2.23.3 Ziopharm Oncology Gene Therapy in Oncology Product and Solutions
2.23.4 Ziopharm Oncology Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Ziopharm Oncology Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Gene Therapy in Oncology Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Gene Therapy in Oncology Players Market Share in 2021
3.2.2 Top 10 Gene Therapy in Oncology Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Gene Therapy in Oncology Players Head Office, Products and Services Provided
3.4 Gene Therapy in Oncology Mergers & Acquisitions
3.5 Gene Therapy in Oncology New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Gene Therapy in Oncology Revenue and Market Share by Type (2017-2022)
4.2 Global Gene Therapy in Oncology Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Gene Therapy in Oncology Revenue Market Share by Application (2017-2022)
5.2 Global Gene Therapy in Oncology Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Gene Therapy in Oncology Revenue by Type (2017-2028)
6.2 North America Gene Therapy in Oncology Revenue by Application (2017-2028)
6.3 North America Gene Therapy in Oncology Market Size by Country
6.3.1 North America Gene Therapy in Oncology Revenue by Country (2017-2028)
6.3.2 United States Gene Therapy in Oncology Market Size and Forecast (2017-2028)
6.3.3 Canada Gene Therapy in Oncology Market Size and Forecast (2017-2028)
6.3.4 Mexico Gene Therapy in Oncology Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Gene Therapy in Oncology Revenue by Type (2017-2028)
7.2 Europe Gene Therapy in Oncology Revenue by Application (2017-2028)
7.3 Europe Gene Therapy in Oncology Market Size by Country
7.3.1 Europe Gene Therapy in Oncology Revenue by Country (2017-2028)
7.3.2 Germany Gene Therapy in Oncology Market Size and Forecast (2017-2028)
7.3.3 France Gene Therapy in Oncology Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Gene Therapy in Oncology Market Size and Forecast (2017-2028)
7.3.5 Russia Gene Therapy in Oncology Market Size and Forecast (2017-2028)
7.3.6 Italy Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Gene Therapy in Oncology Revenue by Type (2017-2028)
8.2 Asia-Pacific Gene Therapy in Oncology Revenue by Application (2017-2028)
8.3 Asia-Pacific Gene Therapy in Oncology Market Size by Region
8.3.1 Asia-Pacific Gene Therapy in Oncology Revenue by Region (2017-2028)
8.3.2 China Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8.3.3 Japan Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8.3.4 South Korea Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8.3.5 India Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Gene Therapy in Oncology Market Size and Forecast (2017-2028)
8.3.7 Australia Gene Therapy in Oncology Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Gene Therapy in Oncology Revenue by Type (2017-2028)
9.2 South America Gene Therapy in Oncology Revenue by Application (2017-2028)
9.3 South America Gene Therapy in Oncology Market Size by Country
9.3.1 South America Gene Therapy in Oncology Revenue by Country (2017-2028)
9.3.2 Brazil Gene Therapy in Oncology Market Size and Forecast (2017-2028)
9.3.3 Argentina Gene Therapy in Oncology Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Gene Therapy in Oncology Revenue by Type (2017-2028)
10.2 Middle East & Africa Gene Therapy in Oncology Revenue by Application (2017-2028)
10.3 Middle East & Africa Gene Therapy in Oncology Market Size by Country
10.3.1 Middle East & Africa Gene Therapy in Oncology Revenue by Country (2017-2028)
10.3.2 Turkey Gene Therapy in Oncology Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Gene Therapy in Oncology Market Size and Forecast (2017-2028)
10.3.4 UAE Gene Therapy in Oncology Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Gene Therapy in Oncology Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Gene Therapy in Oncology Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Gene Therapy in Oncology Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Gene Therapy in Oncology Revenue (USD Million) by Region (2017-2022)
Table 5. Global Gene Therapy in Oncology Revenue Market Share by Region (2023-2028)
Table 6. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol-Myers Squibb Major Business
Table 8. Bristol-Myers Squibb Gene Therapy in Oncology Product and Solutions
Table 9. Bristol-Myers Squibb Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Cold Genesys Corporate Information, Head Office, and Major Competitors
Table 11. Cold Genesys Major Business
Table 12. Cold Genesys Gene Therapy in Oncology Product and Solutions
Table 13. Cold Genesys Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Advantagene Corporate Information, Head Office, and Major Competitors
Table 15. Advantagene Major Business
Table 16. Advantagene Gene Therapy in Oncology Product and Solutions
Table 17. Advantagene Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Amgen Corporate Information, Head Office, and Major Competitors
Table 19. Amgen Major Business
Table 20. Amgen Gene Therapy in Oncology Product and Solutions
Table 21. Amgen Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Gene Therapy in Oncology Product and Solutions
Table 25. AstraZeneca Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Bio-Path Holdings Corporate Information, Head Office, and Major Competitors
Table 27. Bio-Path Holdings Major Business
Table 28. Bio-Path Holdings Gene Therapy in Oncology Product and Solutions
Table 29. Bio-Path Holdings Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. CRISPR Therapeutics Corporate Information, Head Office, and Major Competitors
Table 31. CRISPR Therapeutics Major Business
Table 32. CRISPR Therapeutics Gene Therapy in Oncology Product and Solutions
Table 33. CRISPR Therapeutics Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Editas Medicine Corporate Information, Head Office, and Major Competitors
Table 35. Editas Medicine Major Business
Table 36. Editas Medicine Gene Therapy in Oncology Product and Solutions
Table 37. Editas Medicine Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Geron Corp Corporate Information, Head Office, and Major Competitors
Table 39. Geron Corp Major Business
Table 40. Geron Corp Gene Therapy in Oncology Product and Solutions
Table 41. Geron Corp Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Idera Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 43. Idera Pharmaceuticals Major Business
Table 44. Idera Pharmaceuticals Gene Therapy in Oncology Product and Solutions
Table 45. Idera Pharmaceuticals Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Intellia Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. Intellia Therapeutics Major Business
Table 48. Intellia Therapeutics Gene Therapy in Oncology Product and Solutions
Table 49. Intellia Therapeutics Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 51. Johnson & Johnson Major Business
Table 52. Johnson & Johnson Gene Therapy in Oncology Product and Solutions
Table 53. Johnson & Johnson Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Marsala Biotech Corporate Information, Head Office, and Major Competitors
Table 55. Marsala Biotech Major Business
Table 56. Marsala Biotech Gene Therapy in Oncology Product and Solutions
Table 57. Marsala Biotech Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Merck Corporate Information, Head Office, and Major Competitors
Table 59. Merck Major Business
Table 60. Merck Gene Therapy in Oncology Product and Solutions
Table 61. Merck Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Mologen AG Corporate Information, Head Office, and Major Competitors
Table 63. Mologen AG Major Business
Table 64. Mologen AG Gene Therapy in Oncology Product and Solutions
Table 65. Mologen AG Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Oncolytics Biotech Corporate Information, Head Office, and Major Competitors
Table 67. Oncolytics Biotech Major Business
Table 68. Oncolytics Biotech Gene Therapy in Oncology Product and Solutions
Table 69. Oncolytics Biotech Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Oncosec Corporate Information, Head Office, and Major Competitors
Table 71. Oncosec Major Business
Table 72. Oncosec Gene Therapy in Oncology Product and Solutions
Table 73. Oncosec Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Oncotelic Corporate Information, Head Office, and Major Competitors
Table 75. Oncotelic Major Business
Table 76. Oncotelic Gene Therapy in Oncology Product and Solutions
Table 77. Oncotelic Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Shenzhen SiBiono GeneTech Corporate Information, Head Office, and Major Competitors
Table 79. Shenzhen SiBiono GeneTech Major Business
Table 80. Shenzhen SiBiono GeneTech Gene Therapy in Oncology Product and Solutions
Table 81. Shenzhen SiBiono GeneTech Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Sillajen Biotherapeutics Corporate Information, Head Office, and Major Competitors
Table 83. Sillajen Biotherapeutics Major Business
Table 84. Sillajen Biotherapeutics Gene Therapy in Oncology Product and Solutions
Table 85. Sillajen Biotherapeutics Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Tocagen Corporate Information, Head Office, and Major Competitors
Table 87. Tocagen Major Business
Table 88. Tocagen Gene Therapy in Oncology Product and Solutions
Table 89. Tocagen Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. UniQure Corporate Information, Head Office, and Major Competitors
Table 91. UniQure Major Business
Table 92. UniQure Gene Therapy in Oncology Product and Solutions
Table 93. UniQure Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Ziopharm Oncology Corporate Information, Head Office, and Major Competitors
Table 95. Ziopharm Oncology Major Business
Table 96. Ziopharm Oncology Gene Therapy in Oncology Product and Solutions
Table 97. Ziopharm Oncology Gene Therapy in Oncology Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Global Gene Therapy in Oncology Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 99. Global Gene Therapy in Oncology Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 100. Breakdown of Gene Therapy in Oncology by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Gene Therapy in Oncology Players Head Office, Products and Services Provided
Table 102. Gene Therapy in Oncology Mergers & Acquisitions in the Past Five Years
Table 103. Gene Therapy in Oncology New Entrants and Expansion Plans
Table 104. Global Gene Therapy in Oncology Revenue (USD Million) by Type (2017-2022)
Table 105. Global Gene Therapy in Oncology Revenue Share by Type (2017-2022)
Table 106. Global Gene Therapy in Oncology Revenue Forecast by Type (2023-2028)
Table 107. Global Gene Therapy in Oncology Revenue by Application (2017-2022)
Table 108. Global Gene Therapy in Oncology Revenue Forecast by Application (2023-2028)
Table 109. North America Gene Therapy in Oncology Revenue by Type (2017-2022) & (USD Million)
Table 110. North America Gene Therapy in Oncology Revenue by Type (2023-2028) & (USD Million)
Table 111. North America Gene Therapy in Oncology Revenue by Application (2017-2022) & (USD Million)
Table 112. North America Gene Therapy in Oncology Revenue by Application (2023-2028) & (USD Million)
Table 113. North America Gene Therapy in Oncology Revenue by Country (2017-2022) & (USD Million)
Table 114. North America Gene Therapy in Oncology Revenue by Country (2023-2028) & (USD Million)
Table 115. Europe Gene Therapy in Oncology Revenue by Type (2017-2022) & (USD Million)
Table 116. Europe Gene Therapy in Oncology Revenue by Type (2023-2028) & (USD Million)
Table 117. Europe Gene Therapy in Oncology Revenue by Application (2017-2022) & (USD Million)
Table 118. Europe Gene Therapy in Oncology Revenue by Application (2023-2028) & (USD Million)
Table 119. Europe Gene Therapy in Oncology Revenue by Country (2017-2022) & (USD Million)
Table 120. Europe Gene Therapy in Oncology Revenue by Country (2023-2028) & (USD Million)
Table 121. Asia-Pacific Gene Therapy in Oncology Revenue by Type (2017-2022) & (USD Million)
Table 122. Asia-Pacific Gene Therapy in Oncology Revenue by Type (2023-2028) & (USD Million)
Table 123. Asia-Pacific Gene Therapy in Oncology Revenue by Application (2017-2022) & (USD Million)
Table 124. Asia-Pacific Gene Therapy in Oncology Revenue by Application (2023-2028) & (USD Million)
Table 125. Asia-Pacific Gene Therapy in Oncology Revenue by Region (2017-2022) & (USD Million)
Table 126. Asia-Pacific Gene Therapy in Oncology Revenue by Region (2023-2028) & (USD Million)
Table 127. South America Gene Therapy in Oncology Revenue by Type (2017-2022) & (USD Million)
Table 128. South America Gene Therapy in Oncology Revenue by Type (2023-2028) & (USD Million)
Table 129. South America Gene Therapy in Oncology Revenue by Application (2017-2022) & (USD Million)
Table 130. South America Gene Therapy in Oncology Revenue by Application (2023-2028) & (USD Million)
Table 131. South America Gene Therapy in Oncology Revenue by Country (2017-2022) & (USD Million)
Table 132. South America Gene Therapy in Oncology Revenue by Country (2023-2028) & (USD Million)
Table 133. Middle East & Africa Gene Therapy in Oncology Revenue by Type (2017-2022) & (USD Million)
Table 134. Middle East & Africa Gene Therapy in Oncology Revenue by Type (2023-2028) & (USD Million)
Table 135. Middle East & Africa Gene Therapy in Oncology Revenue by Application (2017-2022) & (USD Million)
Table 136. Middle East & Africa Gene Therapy in Oncology Revenue by Application (2023-2028) & (USD Million)
Table 137. Middle East & Africa Gene Therapy in Oncology Revenue by Country (2017-2022) & (USD Million)
Table 138. Middle East & Africa Gene Therapy in Oncology Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Gene Therapy in Oncology Picture
Figure 2. Global Gene Therapy in Oncology Revenue Market Share by Type in 2021
Figure 3. Ex Vivo
Figure 4. In Vivo
Figure 5. Gene Therapy in Oncology Revenue Market Share by Application in 2021
Figure 6. Hospitals Picture
Figure 7. Diagnostics Centers Picture
Figure 8. Research Institutes Picture
Figure 9. Global Gene Therapy in Oncology Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Gene Therapy in Oncology Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Gene Therapy in Oncology Revenue Market Share by Region (2017-2028)
Figure 12. Global Gene Therapy in Oncology Revenue Market Share by Region in 2021
Figure 13. North America Gene Therapy in Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Gene Therapy in Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Gene Therapy in Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Gene Therapy in Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Gene Therapy in Oncology Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Gene Therapy in Oncology Market Drivers
Figure 19. Gene Therapy in Oncology Market Restraints
Figure 20. Gene Therapy in Oncology Market Trends
Figure 21. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 22. Cold Genesys Recent Developments and Future Plans
Figure 23. Advantagene Recent Developments and Future Plans
Figure 24. Amgen Recent Developments and Future Plans
Figure 25. AstraZeneca Recent Developments and Future Plans
Figure 26. Bio-Path Holdings Recent Developments and Future Plans
Figure 27. CRISPR Therapeutics Recent Developments and Future Plans
Figure 28. Editas Medicine Recent Developments and Future Plans
Figure 29. Geron Corp Recent Developments and Future Plans
Figure 30. Idera Pharmaceuticals Recent Developments and Future Plans
Figure 31. Intellia Therapeutics Recent Developments and Future Plans
Figure 32. Johnson & Johnson Recent Developments and Future Plans
Figure 33. Marsala Biotech Recent Developments and Future Plans
Figure 34. Merck Recent Developments and Future Plans
Figure 35. Mologen AG Recent Developments and Future Plans
Figure 36. Oncolytics Biotech Recent Developments and Future Plans
Figure 37. Oncosec Recent Developments and Future Plans
Figure 38. Oncotelic Recent Developments and Future Plans
Figure 39. Shenzhen SiBiono GeneTech Recent Developments and Future Plans
Figure 40. Sillajen Biotherapeutics Recent Developments and Future Plans
Figure 41. Tocagen Recent Developments and Future Plans
Figure 42. UniQure Recent Developments and Future Plans
Figure 43. Ziopharm Oncology Recent Developments and Future Plans
Figure 44. Global Gene Therapy in Oncology Revenue Share by Players in 2021
Figure 45. Gene Therapy in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players Gene Therapy in Oncology Revenue Market Share in 2021
Figure 47. Global Top 10 Players Gene Therapy in Oncology Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global Gene Therapy in Oncology Revenue Share by Type in 2021
Figure 50. Global Gene Therapy in Oncology Market Share Forecast by Type (2023-2028)
Figure 51. Global Gene Therapy in Oncology Revenue Share by Application in 2021
Figure 52. Global Gene Therapy in Oncology Market Share Forecast by Application (2023-2028)
Figure 53. North America Gene Therapy in Oncology Sales Market Share by Type (2017-2028)
Figure 54. North America Gene Therapy in Oncology Sales Market Share by Application (2017-2028)
Figure 55. North America Gene Therapy in Oncology Revenue Market Share by Country (2017-2028)
Figure 56. United States Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe Gene Therapy in Oncology Sales Market Share by Type (2017-2028)
Figure 60. Europe Gene Therapy in Oncology Sales Market Share by Application (2017-2028)
Figure 61. Europe Gene Therapy in Oncology Revenue Market Share by Country (2017-2028)
Figure 62. Germany Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific Gene Therapy in Oncology Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific Gene Therapy in Oncology Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific Gene Therapy in Oncology Revenue Market Share by Region (2017-2028)
Figure 70. China Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America Gene Therapy in Oncology Sales Market Share by Type (2017-2028)
Figure 77. South America Gene Therapy in Oncology Sales Market Share by Application (2017-2028)
Figure 78. South America Gene Therapy in Oncology Revenue Market Share by Country (2017-2028)
Figure 79. Brazil Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa Gene Therapy in Oncology Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Gene Therapy in Oncology Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Gene Therapy in Oncology Revenue Market Share by Country (2017-2028)
Figure 84. Turkey Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE Gene Therapy in Oncology Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
